This fusion protein has the characteristic of tumor-specific targeting and blocking the PD-1/PD-L1 interaction through the αPD-L1 arm, while also preferentially enhancing the activation and proliferation of CD8+ T cells over Tregs due to the attenuated affinity of the novel IL-2v for IL-2Rβγ and lack of affinity for IL-2Rα, resulting in anti-tumor activity. The gene discussed is CD8A; the disease is neoplasm.